Indivior Eliminates Chief Scientific Officer Role, Reports Annual Meeting Results
INDV has more than doubled off its 52-week low of $10.63.
Summary
Indivior Pharmaceuticals is eliminating the Chief Scientific Officer role, with Dr. Christian Heidbreder departing at year-end, while shareholders approved all proposals at the annual meeting.
Key Events · Executive and Board Changes · INDV
-
Chief Scientific Officer Role Eliminated
Dr. Christian Heidbreder's position as Chief Scientific Officer will be eliminated effective June 1, 2026. He will continue in an advisory capacity until his employment terminates on December 31, 2026, treated as a termination without cause.
-
Annual Meeting Results Approved
Shareholders approved all proposals at the annual meeting held on May 13, 2026. This included the election of eight director nominees, advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP US as the independent auditor for 2026. Shareholders also indicated a preference for annual 'say-on-pay' votes.
Analysis · INDV · Life Sciences
Indivior Pharmaceuticals announced the elimination of its Chief Scientific Officer position, with Dr. Christian Heidbreder transitioning to an advisory role before his employment terminates at year-end. This executive change could signal a strategic shift in the company's research and development focus or structure. Separately, shareholders approved all proposals at the annual meeting, including the election of directors, executive compensation, and the appointment of the independent auditor.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDV was trading at $36.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $10.63 to $41.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.